France Payroll Lead
About the job
- A higher education degree in Finance, Accounting, Business Administration, Human Resources, or an equivalent field.
- Fluent French and professional English.
- At least 5 years of experience in French payroll, with responsibility for complete payroll cycles.
- Strong knowledge of French payroll and social regulations.
- Demonstrated experience managing end-to-end payroll, including inputs, processing, outputs, and controls.
- Experience collaborating with payroll providers and managing service quality.
- Experience with time and attendance processes (GTA).
- Advanced Excel proficiency.
- Experience in a Global Business Services, shared services center, business process outsourcing, or international environment.
- Strong analytical and problem-solving capabilities.
- Lead and coordinate end-to-end French payroll operations, ensuring deadlines, regulatory compliance, and processing quality.
- Manage the full payroll cycle, including payroll inputs, validations, calculations, outputs, controls, and preparation of final payroll validation.
- Ensure payroll accuracy through robust controls, reconciliations, and proactive anomaly management.
- Oversee and support time and attendance activities to ensure employee data is reliable and correctly integrated into payroll.
- Work closely with the payroll provider to ensure service quality, incident resolution, and operational performance.
- Serve as the primary escalation point for operational payroll matters and coordinate corrective actions when needed.
- Participate in accounting reconciliations with the payroll provider and Finance teams.
- Provide expert support to HR teams and stakeholders on complex situations, including hires, departures, contract changes, adjustments, absences, and regulatory impacts.
- Handle employee queries related to payroll and time and attendance efficiently and within defined service levels.
- Prepare payroll reports, performance indicators, analyses, and follow-up communications.
- Maintain and update payroll process documentation.
- Identify opportunities to simplify, optimize, and continuously improve processes and controls.
- Participate in payroll projects, audits, tool changes, provider transitions, and transformation initiatives.
- Collaborate with regional and global teams to align payroll operations.
- Experience with other European or international markets.
- Interest in or willingness to develop exposure to international payroll environments and multi-country organizations.
- Experience with payroll transition, transformation, or stabilization projects.
- Experience managing environments with multiple stakeholders.
- Focus on continuous improvement and operational excellence.
Contexte du poste
Au sein de notre organisation Global Business Services, vous serez responsable du pilotage et de la coordination des opérations de paie de bout en bout pour la France, afin de garantir une paie juste, conforme et réalisée dans les délais, dans le respect de la réglementation locale et des contrôles internes.
Vous serez l’interlocuteur principal pour les activités de paie France et travaillerez en étroite collaboration avec les équipes RH locales, les collaborateurs, le prestataire paie, la Finance ainsi que les parties prenantes internes afin d’assurer l’excellence opérationnelle, la qualité de la paie et l’amélioration continue des processus.
Ce poste requiert une solide expérience opérationnelle en paie, une forte capacité de prise en charge des sujets ainsi qu’une aptitude à piloter la résolution des incidents et la stabilisation des opérations dans un environnement dynamique. Une exposition à des environnements internationaux ou un intérêt pour des sujets paie au-delà du périmètre France sera considéré comme un atout.
Missions principales
- Piloter et coordonner les opérations de paie France de bout en bout, en garantissant le respect des délais, la conformité réglementaire et la qualité des traitements.
- Assurer le pilotage du cycle complet de paie incluant les inputs paie, validations, calculs, outputs paie, contrôles et préparation de la validation finale de paie.
- Garantir l’exactitude de la paie grâce à des contrôles robustes, des rapprochements et une gestion proactive des anomalies.
- Superviser et accompagner les activités GTA (Gestion des Temps et Activités) afin de garantir la fiabilité des données collaborateurs et leur bonne intégration en paie.
- Collaborer étroitement avec le prestataire paie afin d’assurer la qualité du service, la résolution des incidents et la performance opérationnelle.
- Être le point d’escalade principal pour les sujets opérationnels liés à la paie et coordonner les actions correctives lorsque nécessaire.
- Participer aux activités de rapprochement comptable avec le prestataire paie et les équipes Finance.
- Apporter un support expert aux équipes RH et aux parties prenantes sur les situations complexes : entrées, sorties, modifications contractuelles, régularisations, absences et impacts réglementaires.
- Garantir un traitement efficace des demandes collaborateurs liées à la paie et à la GTA dans le respect des niveaux de service définis.
- Préparer les reportings paie, indicateurs de performance, analyses et communications de suivi.
- Maintenir la documentation des processus paie et veiller à sa mise à jour.
- Identifier des opportunités de simplification, d’optimisation et d’amélioration continue des processus et contrôles.
- Participer aux projets paie, audits, changements d’outils, transitions prestataires et initiatives de transformation.
- Collaborer avec les équipes régionales et globales afin d’assurer l’alignement des opérations paie.
Profil recherché
Vous êtes un professionnel expérimenté de la paie avec une forte expertise de la paie française et de ses obligations réglementaires. Vous combinez excellence opérationnelle, sens du service et capacité à gérer des sujets complexes avec différents interlocuteurs.
Compétences requises
- Diplôme supérieur en Finance, Comptabilité, Administration des entreprises, Ressources Humaines ou domaine équivalent.
- Français courant et anglais professionnel.
- Minimum 5 ans d’expérience en paie France, avec responsabilité sur des cycles de paie complets.
- Solide connaissance de la réglementation paie et sociale française.
- Expérience confirmée dans la gestion de la paie de bout en bout (inputs, traitements, outputs et contrôles).
- Expérience de collaboration avec des prestataires paie et pilotage de la qualité de service.
- Expérience des processus GTA / Gestion des Temps et Activités.
- Bonnes capacités d’analyse et de résolution de problèmes.
- Maîtrise avancée d’Excel.
- Expérience en environnement GBS, SSC, BPO ou international.
Compétences appréciées
- Une expérience sur d’autres marchés européens ou internationaux est un plus.
- Intérêt ou volonté de développer une exposition à des environnements paie internationaux et à des organisations multi-pays.
- Expérience sur des projets de transition, transformation ou stabilisation paie.
- Expérience dans la gestion d’environnements avec de multiples parties prenantes.
- Sens de l’amélioration continue et de l’excellence opérationnelle.
Rémunération : de 47 000 € à 61 000 € brut annuel, selon l'expérience et les qualifications.
Localisation : France
Mode de travail : Hybride (2 jours par semaine sur site, le reste en télétravail)
Autorisation de travail : Le candidat doit disposer d’une autorisation légale de travail en France.
Job Level: Professional
Why Biogen?
We are a global team with a commitment to excellence, and a pioneering spirit. As a mid-sized biotechnology company, we provide the stability and resources of a well-established business while fostering an environment where individual contributions make a significant impact. Our team encompasses some of the most talented and passionate achievers who have unparalleled opportunities for learning, growth, and expanding their skills. Above all, we work together to deliver life-changing medicines, with every role playing a vital part in our mission. Caring Deeply. Achieving Excellence. Changing Lives.
At Biogen, we are committed to building on our culture of inclusion and belonging that reflects the communities where we operate and the patients we serve. We know that diverse backgrounds, cultures, and perspectives make us a stronger and more innovative company, and we are focused on building teams where every employee feels empowered and inspired. Read on to learn more about Biogen.
All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.
About the company
Biogen is a global biotechnology company focused on neuroscience. It discovers, develops, and delivers therapies for neurological disorders, such as multiple sclerosis and other neurodegenerative diseases. Its product process starts with research and development to identify potential drugs, followed by clinical testing and regulatory approval, ultimately leading to commercialization and patient treatment. Biogen differentiates itself through a long history (founded in 1978), a deep specialization in neuroscience, and an integrated pipeline that moves ideas from discovery to approved medicines, aiming to create value for shareholders while helping communities. The company’s goal is to advance therapies for neurological diseases to improve patients’ lives and generate sustainable value for stakeholders.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
1978
Get referred to Biogen
See people who can refer or advise you
Simplify's Take
What believers are saying
- LEQEMBI Pen won Japan approval on September 16, 2026, expanding at-home dosing.
- China approved LEQEMBI subcutaneous initiation on September 3, 2026, accelerating access.
- Apellis closed on May 14, 2026, adding SYFOVRE and EMPAVELI revenue.
What critics are saying
- Biogen halted BIIB122 after May 21, 2026 Phase 2b failure in Parkinson’s disease.
- Genentech won $124.3 million against Biogen in November 2025; appeal remains pending.
- TECFIDERA exclusivity expired, generics spread, and 1,400 layoffs expose franchise erosion.
What makes Biogen unique
- Biogen pairs neuroscience depth with marketed Alzheimer’s, MS, and rare-disease franchises.
- Eisai-Biogen launched LEQEMBI IQLIK in the U.S. on August 24, 2026.
- Biogen and Stoke advanced zorevunersen into Phase 3 EMPEROR for Dravet syndrome.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Remote Work Options
- Professional Development Budget
Growth & Insights and Company News
6 month growth
-10%1 year growth
-10%2 year growth
-10%City Therapeutics raises $200M for RNAi beyond the liver. City Therapeutics' $200 million IPO backs RNAi development beyond the liver, with an anticoagulant contender and partnerships in eye and brain diseases. Key facts. * IPO proceeds: City Therapeutics raised $200 million in an upsized initial public offering. * Lead therapy: An RNA interference candidate could become an alternative to blockbuster-selling anticoagulants. * Eye-disease partnership: City Therapeutics has a partnership with Bausch + Lomb in eye diseases. * Central nervous system partnership: City Therapeutics has a partnership with Biogen in central nervous system disorders. City Therapeutics raised $200 million in an upsized initial public offering to advance RNA interference medicines, including a platform aimed at reaching tissues beyond the liver. City Therapeutics has raised $200 million in an upsized initial public offering, securing capital for a drug-development strategy that reaches beyond the liver, an important destination for RNA interference medicines. Its investment case combines a lead therapy that could offer an alternative to established anticoagulants with technology intended to deliver gene-silencing drugs to other tissues. The financing addresses a central challenge in biotechnology: turning a promising way of intervening in disease into medicines that can reach the right cells safely and reliably. City also has partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system disorders. Those relationships give the platform a broader development footprint, but they do not establish that its experimental treatments will work. More capital, but no shortcut to clinical evidence. The upsized offering raised $200 million, according to MedCity News. The financing gives City resources to pursue its pipeline and delivery technology. It does not, on its own, resolve the scientific and clinical risks that will determine their value. The distinction matters because an IPO measures a company's ability to secure funding, not the effectiveness of its medicines. A larger offering can support development work, but investors still need evidence that a treatment produces its intended biological effect and that the effect translates into a benefit for patients. The supplied offering details do not establish a share price, valuation, net proceeds after expenses or a program-by-program spending plan. Without those terms, the amount raised cannot support a precise judgment about dilution, cash runway or how much capital will reach any particular therapy. The sounder focus is what evidence the financing may help City generate. Why delivery beyond the liver matters. RNA interference, or RNAi, is a way to reduce production of a selected protein by targeting the molecular instructions used to make it. Rather than directly blocking a protein after it has been produced, an RNAi medicine seeks to interrupt the process upstream. Its therapeutic usefulness depends on choosing a suitable target and delivering the treatment to the cells that matter. Delivery is therefore part of the medicine's core design, not merely a packaging problem. A treatment must reach the relevant tissue, enter the appropriate cells and remain active long enough to produce a useful effect. Success at silencing a target in one setting does not automatically establish that the same approach will succeed elsewhere in the body. For City, expansion beyond the liver could widen the range of diseases its technology can address. But that opportunity also sets a demanding standard of proof. Investors will need to distinguish evidence that a drug reaches a tissue from evidence that it changes the course of disease. Both are important, and neither should be assumed from the platform's ambition. The anticoagulant opportunity rests on patient benefit. City's lead RNAi therapy could become an alternative to blockbuster-selling anticoagulants. That places the program against an established treatment category rather than a market with no existing options. The commercial opportunity is meaningful in principle, but the description of a potential alternative is not evidence of superiority. City's lead RNAi therapy could become an alternative to blockbuster-selling anticoagulants. Anticoagulants reduce the blood's ability to form clots. Their clinical use involves balancing protection against harmful clotting with the risk of bleeding. Any new approach seeking a role in that treatment landscape must demonstrate a useful balance of benefit and risk in the patients for whom it is intended. For an RNAi candidate, the connection between gene silencing and patient outcomes will be central. Showing that a target has been suppressed is different from showing that patients experience fewer harmful events or an acceptable safety profile. Duration of action and the ability to manage treatment around changing medical needs would also be relevant questions, rather than advantages investors should presume. The available facts do not identify the lead therapy's target, trial stage, dosing schedule or clinical results. They therefore support an opportunity to investigate, not a forecast that City will displace existing medicines. Partnerships broaden the platform's reach. The Bausch + Lomb and Biogen partnerships extend City's work into eye diseases and central nervous system disorders, respectively. They provide concrete examples of how the company's RNAi design and delivery technology is being pursued outside its lead program. These relationships matter because a platform business depends on more than the prospects of an individual drug. If technology can support useful medicines across distinct tissues and diseases, it may create additional development opportunities. Conversely, a result in one program may say little about another when the target cells, delivery requirements and disease biology differ. The partnerships should not be treated as interchangeable proof points. Work in eye disease cannot by itself validate a treatment for a central nervous system disorder, and neither establishes the clinical prospects of the anticoagulant alternative. No partnership payments, milestone amounts or royalty terms are supplied. Investors consequently cannot use these relationships to calculate a dependable stream of future cash. Their demonstrated significance here is the breadth of the development relationships, not a quantifiable contribution to revenue. What investors should watch after the IPO. The next useful disclosures would connect City's financing to a clear development plan: which programs it intends to prioritize, what studies are designed to establish and how spending is divided between individual candidates and the delivery platform. Those details would help investors judge whether the company is pursuing a focused set of testable objectives. For the lead therapy, attention should fall on clinical evidence relevant to anticoagulant use, rather than molecular activity alone. For the broader platform, the important question is whether delivery outside the liver can produce reproducible, therapeutically useful results without unacceptable safety costs. City's $200 million IPO provides capital to pursue those questions. Its partnerships broaden the scope of the effort, while the lead program gives investors a specific potential commercial application to assess. The financing is a consequential step, but the investment case ultimately depends on what the company can demonstrate with that capital - not simply how much it raised. Frequently asked questions. How much did City Therapeutics raise in its IPO? City Therapeutics raised $200 million in an upsized initial public offering. The financing supports a company developing RNA interference medicines and technology intended to reach tissues beyond the liver. The available facts do not specify the offering's share price, valuation, net proceeds after expenses or allocation of funding among programs. What is RNA interference? RNA interference, or RNAi, reduces production of a selected protein by targeting the molecular instructions used to make it. For a treatment to work, it must reach the appropriate cells and produce a useful biological effect. Successful target suppression must then translate into meaningful patient benefit with an acceptable safety profile. Why is City Therapeutics pursuing RNAi beyond the liver? Reaching tissues beyond the liver could allow City Therapeutics to pursue a broader range of diseases. Delivery is a central challenge because an RNAi medicine must enter the relevant cells to act. Evidence of delivery is important, but it does not by itself establish that a treatment improves patient outcomes. What is the opportunity for City's lead therapy? City Therapeutics' lead RNAi therapy could become an alternative to blockbuster-selling anticoagulants. That creates a potential opportunity in an established treatment category, but does not demonstrate an advantage over existing medicines. The supplied facts do not identify the candidate's target, clinical stage, dosing schedule or results. Which companies have partnerships with City Therapeutics? City Therapeutics has partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system disorders. These relationships broaden the applications being pursued with its technology. They do not establish clinical success, and the supplied facts contain no payments, milestones or royalty terms from which to estimate future revenue. What should investors watch following the IPO? Investors should watch for program priorities, spending plans and evidence connecting RNAi activity to patient benefit. For the lead therapy, efficacy and safety relevant to anticoagulant use will matter. For the broader platform, the central question is whether delivery beyond the liver produces reproducible, therapeutically useful results.
Arrowhead's blood-brain barrier tech is 'arguably better' than others, analysts say after data drop. October 15, 2026 | Arrowhead Pharmaceuticals' siRNA candidate achieved "compelling" tau reductions in an early study of healthy volunteers, with a magnitude of effect that seems to outperform other blood-brain barrier platforms, according to Stifel. Arrowhead Pharmaceuticals' investigational gene silencer lowered tau protein levels in an early study, suggesting that the biotech's approach to bypass the blood-brain barrier may be better than competing technologies. The findings "provide important clinical validation" for Arrowhead's platform for targeting the central nervous system through subcutaneously administered drugs, Stifel analysts said in a Wednesday note. Results from the Phase 1/2a study, disclosed Wednesday, showed a 40% average reduction in CSF tau at day 105 in healthy volunteers who were treated with the low 2.1-mg/kg dose of the siRNA candidate, called ARO-MAPT, on days 1, 8 and 15. In those given a 6.4-mg/kg dose on the same days, CSF tau dropped by 69% on average at day 105. Meanwhile, a 12.8-mg/kg dose of ARO-MAPT injected on days 1 and 15 triggered a mean CSF tau reduction of 73% at day 105. The maximum CSF tau reduction reached 85% in the high-dose cohort. The early trial is actively enrolling patients, with a target of 112 participants, including healthy volunteers for the study's first part and patients with early Alzheimer's disease for the second portion. Wednesday's data came from healthy volunteers. As for safety, the primary objective of the Phase 1/2a trial, Arrowhead said that ARO-MAPT was "generally well tolerated." Treatment-emergent adverse events were largely mild, with no serious side effects, deaths or dropouts due to toxicities. The data, while early, could set Arrowhead up to compete against Biogen, analysts say. Both companies are advancing tau-targeting therapies that work by suppressing the expression of the MAPT gene, which codes for the tau protein. "While details are still relatively light, the data looking compelling," Stifel told investors in a note on Wednesday, adding that the interim findings are "arguably better than what we've seen with other BBB platforms." The firm also hinted at a potential competitive edge for Arrowhead's subcutaneous siRNA asset, writing that the CSF tau knockdown "looks better than [Biogen's] BIIB080," an anti-tau antisense oligonucleotide also known as diranersen that is injected directly into the spine. ARO-MAPT, meanwhile, can be delivered via an injection under the skin. Phase 1b data for diranersen published in 2023 showed that, across various dose levels, CSF tau declined by an average of 30% to 49% at eight weeks after the final dose of Biogen's asset. Diranersen's tau-lowering effect persisted through 24 weeks after the last dose, hitting an average tau reduction of up to 56%. The trial enrolled 46 patients with mild Alzheimer's disease, and its primary endpoint was safety; CSF tau was set as a key exploratory outcome. There have been no direct head-to-head studies between ARO-MAPT and diranersen, which prompted Jefferies to be a bit more reserved about comparing the two assets. The firm in a Wednesday note pointed to differences in study populations and dose strengths. In May, Biogen announced that diranersen failed to meet its primary goal of showing a dose-response effect in cognitive and functional outcomes in the Phase 2 CELIA study. Nevertheless, the company detected "robust reductions in tau pathology" that were consistent with the Phase 1b study. Biogen also touted cognitive improvements and slowing of decline, especially in patients who received the lowest dose of diranersen. Based on these efficacy signals, Biogen has decided to push diranersen into registrational development, though the company has yet to specify a timeline for this. Arrowhead is also moving forward with ARO-MAPT, with additional healthy volunteer and Alzheimer's disease data expected next year. Arrowhead is also in talks with health regulators to enable studies in MAPT-associated frontotemporal dementia and progressive supranuclear palsy, according to the Wednesday announcement.
Investment research site StockStory picked two stocks to buy and one to avoid among companies trading near 52-week highs. It likes Mastercard and ConocoPhillips, and advises selling Biogen. Mastercard trades at $588.84 per share, or 27x forward earnings. Its revenue grew 16.1% a year over five years, and its return on equity is 182%. ConocoPhillips trades at $134.30, or 12.3x forward earnings. Its revenue grew 10.1% a year over ten years, and its revenue stands at $65.28 billion. Biogen trades at $224.63, or 16.5x forward earnings. Its revenue fell 3% a year over five years, and its earnings per share have declined.
Trigeminal Neuralgia Pipeline Outlook highlights 10+ Companies and 10+ emerging therapies across clinical development stages. September 29 Trigeminal Neuralgia is a chronic neuropathic pain disorder characterized by spontaneous and elicited paroxysms of electric shock-like or stabbing pain in a region of the face, most frequently affecting the distribution of the second (maxillary) or third (mandibular) division of the trigeminal nerve, with the right side of the face affected more often than the left. (Albany, US) September 28, 2026 - DelveInsight's "Trigeminal Neuralgia - Pipeline Insight, 2026" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Trigeminal Neuralgia pipeline landscape, covering clinical and nonclinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type, as well as inactive pipeline products. Three types of trigeminal neuralgia have been delineated: classical, secondary, and idiopathic, with bilateral trigeminal neuralgia rare and warranting concern about an underlying neurologic or non-neurologic disorder affecting the cranium. Incidence is higher among women than men and increases with age. Key Takeaways from the Trigeminal Neuralgia Pipeline Report * The Trigeminal Neuralgia pipeline includes 10+ key companies developing therapies, with 10+ products spanning Phase III, Phase II, Phase I, preclinical, and discovery stages, along with discontinued and inactive candidates. * Biogen has the most advanced Trigeminal Neuralgia drug candidate in the pipeline, with Vixotrigine (BIIB074) currently in Phase III development. * Vixotrigine is a centrally and peripherally acting small molecule that functions as a voltage- and use-dependent sodium channel blocker, being developed by Biogen for the treatment of Trigeminal Neuralgia. * Rimegepant, developed by Biohaven Pharmaceuticals, is a calcitonin gene-related peptide (CGRP) receptor antagonist in Phase II development for Trigeminal Neuralgia, with a trial initiated in June 2019. * The pipeline includes therapies across multiple stages of development, highlighting continued innovation in neuropathic pain treatment. * Emerging therapies are being developed through diverse mechanisms, including sodium channel blockers and CGRP receptor antagonists. Gain Strategic Insights into the Trigeminal Neuralgia Pipeline Landscape * Explore the complete Trigeminal Neuralgia Pipeline Outlook. * Analyze Phase III, Phase II, Phase I, preclinical, and discovery-stage assets. * Evaluate emerging companies and late-stage pipeline therapies. * Understand therapeutic assessment by product type, route of administration, and molecule type. * Track collaborations, licensing, acquisitions, and other pipeline development activities. Explore detailed pipeline insights and emerging therapies @ Trigeminal Neuralgia Pipeline Insight Report Trigeminal Neuralgia Disease Overview Pain can be triggered by routine acts, including brushing teeth, shaving, touching the face, eating or drinking, speaking, or a breeze on the face. Diagnosis is clinical, based on pain restricted to the territory of one or more divisions of the trigeminal nerve and sudden, intense, very short paroxysms. The anticonvulsant agents carbamazepine and oxcarbazepine have been considered first-choice treatments for control of paroxysmal pain, with gabapentin, pregabalin, and antidepressant agents tried as additional agents. Microvascular decompression is favored as the surgical procedure for cases not responding to medication. Trigeminal Neuralgia Emerging Drugs Analysis The Trigeminal Neuralgia pipeline features multiple emerging therapies targeting neuropathic pain through novel mechanisms and differentiated therapeutic approaches. Phase III Therapy * Vixotrigine (BIIB074): Biogen - A centrally and peripherally acting small molecule voltage- and use-dependent sodium channel blocker. It is currently the most advanced candidate in the Trigeminal Neuralgia pipeline and is being evaluated in Phase III clinical development. Phase II Therapy * Rimegepant: Biohaven Pharmaceuticals - A calcitonin gene-related peptide (CGRP) receptor antagonist currently being evaluated in Phase II development for Trigeminal Neuralgia, with clinical development initiated in June 2019. Further product details on additional pipeline candidates are provided in the full report. Trigeminal Neuralgia Therapeutic Assessment The report provides comprehensive therapeutic assessment of Trigeminal Neuralgia drugs across multiple development and product parameters. Clinical Trial Phases * Late-stage products (Phase III). * Mid-stage products (Phase II). * Early-stage products (Phase I). * Preclinical candidates. * Discovery-stage candidates. * Discontinued and inactive pipeline candidates. Route of Administration * Intravenous. * Subcutaneous. * Oral. * Intramuscular. Molecule Type * Monoclonal antibody. * Small molecule. * Peptide. Product Type * Mono. * Combination. * Mono/Combination. Trigeminal Neuralgia Pipeline Development Landscape The Trigeminal Neuralgia pipeline reflects ongoing innovation across clinical and preclinical development, with multiple companies advancing therapies targeting neuropathic pain through differentiated mechanisms of action. The pipeline spans early discovery through Phase III clinical development and includes both active and inactive candidates, providing insights into the evolving research landscape. Discover Which Companies and Pipeline Therapies Are Advancing Trigeminal Neuralgia Treatment @ Trigeminal Neuralgia Pipeline Insights Scope of the Trigeminal Neuralgia Pipeline Report * Geography Covered: Global. * Coverage: 10+ companies and 10+ pipeline drugs across clinical and nonclinical development stages. * Clinical Stages Covered: Phase III, Phase II, Phase I, preclinical, discovery, inactive, and discontinued products. * Therapeutic Assessment: Product type, clinical stage, route of administration, and molecule type. * Additional Coverage: Collaborations, acquisitions and mergers, licensing, designations, and other product-related development activities. About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides actionable market intelligence and strategic insights across the pharmaceutical, biotechnology, and healthcare industries. With expertise in epidemiology forecasting, competitive intelligence, and pipeline analysis, DelveInsight helps organizations make informed business decisions and stay ahead in an evolving healthcare landscape. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Mehul Malhotra Email: Send Email Phone: 09650213330 Address:A-1 NV 89107 City: delhi State: Indiana Country: United States Website: https://www.delveinsight.com/
Trigeminal Neuralgia Pipeline Outlook highlights 10+ Companies and 10+ emerging therapies across clinical development stages. September 29 Trigeminal Neuralgia is a chronic neuropathic pain disorder characterized by spontaneous and elicited paroxysms of electric shock-like or stabbing pain in a region of the face, most frequently affecting the distribution of the second (maxillary) or third (mandibular) division of the trigeminal nerve, with the right side of the face affected more often than the left. (Albany, US) September 28, 2026 - DelveInsight's "Trigeminal Neuralgia - Pipeline Insight, 2026" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Trigeminal Neuralgia pipeline landscape, covering clinical and nonclinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type, as well as inactive pipeline products. Geographic Reference Three types of trigeminal neuralgia have been delineated: classical, secondary, and idiopathic, with bilateral trigeminal neuralgia rare and warranting concern about an underlying neurologic or non-neurologic disorder affecting the cranium. Incidence is higher among women than men and increases with age. Key Takeaways from the Trigeminal Neuralgia Pipeline Report * The Trigeminal Neuralgia pipeline includes 10+ key companies developing therapies, with 10+ products spanning Phase III, Phase II, Phase I, preclinical, and discovery stages, along with discontinued and inactive candidates. * Biogen has the most advanced Trigeminal Neuralgia drug candidate in the pipeline, with Vixotrigine (BIIB074) currently in Phase III development. * Vixotrigine is a centrally and peripherally acting small molecule that functions as a voltage- and use-dependent sodium channel blocker, being developed by Biogen for the treatment of Trigeminal Neuralgia. * Rimegepant, developed by Biohaven Pharmaceuticals, is a calcitonin gene-related peptide (CGRP) receptor antagonist in Phase II development for Trigeminal Neuralgia, with a trial initiated in June 2019. * The pipeline includes therapies across multiple stages of development, highlighting continued innovation in neuropathic pain treatment. * Emerging therapies are being developed through diverse mechanisms, including sodium channel blockers and CGRP receptor antagonists. Gain Strategic Insights into the Trigeminal Neuralgia Pipeline Landscape * Explore the complete Trigeminal Neuralgia Pipeline Outlook. * Analyze Phase III, Phase II, Phase I, preclinical, and discovery-stage assets. * Evaluate emerging companies and late-stage pipeline therapies. * Understand therapeutic assessment by product type, route of administration, and molecule type. * Track collaborations, licensing, acquisitions, and other pipeline development activities. Explore detailed pipeline insights and emerging therapies @ Trigeminal Neuralgia Pipeline Insight Report Trigeminal Neuralgia Disease Overview Pain can be triggered by routine acts, including brushing teeth, shaving, touching the face, eating or drinking, speaking, or a breeze on the face. Diagnosis is clinical, based on pain restricted to the territory of one or more divisions of the trigeminal nerve and sudden, intense, very short paroxysms. The anticonvulsant agents carbamazepine and oxcarbazepine have been considered first-choice treatments for control of paroxysmal pain, with gabapentin, pregabalin, and antidepressant agents tried as additional agents. Microvascular decompression is favored as the surgical procedure for cases not responding to medication. Trigeminal Neuralgia Emerging Drugs Analysis The Trigeminal Neuralgia pipeline features multiple emerging therapies targeting neuropathic pain through novel mechanisms and differentiated therapeutic approaches. Phase III Therapy Counseling Services * Vixotrigine (BIIB074): Biogen - A centrally and peripherally acting small molecule voltage- and use-dependent sodium channel blocker. It is currently the most advanced candidate in the Trigeminal Neuralgia pipeline and is being evaluated in Phase III clinical development. Phase II Therapy * Rimegepant: Biohaven Pharmaceuticals - A calcitonin gene-related peptide (CGRP) receptor antagonist currently being evaluated in Phase II development for Trigeminal Neuralgia, with clinical development initiated in June 2019. Further product details on additional pipeline candidates are provided in the full report. Trigeminal Neuralgia Therapeutic Assessment The report provides comprehensive therapeutic assessment of Trigeminal Neuralgia drugs across multiple development and product parameters. Clinical Trial Phases * Late-stage products (Phase III). * Mid-stage products (Phase II). * Early-stage products (Phase I). * Preclinical candidates. * Discovery-stage candidates. * Discontinued and inactive pipeline candidates. Route of Administration * Intravenous. * Subcutaneous. * Oral. * Intramuscular. Molecule Type * Monoclonal antibody. * Small molecule. * Peptide. Product Type * Mono. * Combination. * Mono/Combination. Trigeminal Neuralgia Pipeline Development Landscape The Trigeminal Neuralgia pipeline reflects ongoing innovation across clinical and preclinical development, with multiple companies advancing therapies targeting neuropathic pain through differentiated mechanisms of action. The pipeline spans early discovery through Phase III clinical development and includes both active and inactive candidates, providing insights into the evolving research landscape. Discover Which Companies and Pipeline Therapies Are Advancing Trigeminal Neuralgia Treatment @ Trigeminal Neuralgia Pipeline Insights Counseling Services Scope of the Trigeminal Neuralgia Pipeline Report * Geography Covered: Global. * Coverage: 10+ companies and 10+ pipeline drugs across clinical and nonclinical development stages. * Clinical Stages Covered: Phase III, Phase II, Phase I, preclinical, discovery, inactive, and discontinued products. * Therapeutic Assessment: Product type, clinical stage, route of administration, and molecule type. * Additional Coverage: Collaborations, acquisitions and mergers, licensing, designations, and other product-related development activities. About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides actionable market intelligence and strategic insights across the pharmaceutical, biotechnology, and healthcare industries. With expertise in epidemiology forecasting, competitive intelligence, and pipeline analysis, DelveInsight helps organizations make informed business decisions and stay ahead in an evolving healthcare landscape. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Mehul Malhotra Email: Send Email Phone: 09650213330 Address:A-1 NV 89107 City: delhi State: Indiana Country: United States Website: https://www.delveinsight.com/